Seeking Alpha

KarinCA

 
View as an RSS Feed
View KarinCA's Comments BY TICKER:
Latest  |  Highest rated
  • Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon [View article]
    Small Pharma Analyst... Abacavir as a treatment for psoriasis came out of anecdotal experience of HIV patients who also suffered from the inflammatory disease. Most famously, Magic Johnson claimed that a benefit of his Abacavir treatment was the complete clearing up of his psoriasis.

    Clinically, this could not be duplicated sufficiently to warrant off-label usage. Plus, Abacavir has some side effects that limit its use for non-life threatening conditions. Prurisol is more than just a salt of Abacavir that converts to Abacavir in the system. Prurisol is a compound that includes the salt of Abacavir which minimizes side effects and the compound includes adjuvants for increased efficacy.

    Due to the crossover trial being successful, the Company will initiate a larger Phase 2 clinical trial under the 505(b)(2) designation. The FDA is permitting Prurisol to move to an advanced trial because the active moiety of Prurisol is that of a drug already approved by the FDA. This is a huge time saver.

    Just like the FDA granting Brilacidin QIDP status is a huge time saver along with adding another five years to the patent life. ;)
    Jan 31, 2015. 05:40 PM | Likes Like |Link to Comment
  • Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon [View article]
    dpudvay... I forgot to add Dr Jorgenson is the Chief Medical Officer CMO since their web site hasn't been updated to include him yet. He was added effective January 1, 2015. That makes four key people now.

    http://bit.ly/1BIMkeW

    http://bit.ly/1BIMkeX

    Leo Ehrlich, CPA - Chief Executive Officer and CFO, Board of Directors Krishna Menon, RCM, PhD, VMD - President, Chief Scientific Officer, Board of Directors
    James Alexander, MD, MPH, FACP – Chief Operating Officer
    Daniel Jorgenson MD, MPH, MBA - Chief Medical Officer

    Dr Jorgensen is the only one I didn't get to meet when I attended the Biotech Showcase earlier this month. He was busy in a meeting that must have been important since Dr Alexander replaced him in the presentation.

    Leo has made it clear he wants to uplist this year and will add independent directors at that time.
    Jan 31, 2015. 11:33 AM | Likes Like |Link to Comment
  • Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon [View article]
    The $4.80 was in response to the number you used in the comment I responded to. I certainly know what the high was. ;)

    Leo told us in the q&a after the presentation at the Biotech Showcase that they will uplist in 2015 and are looking for board members that will be added at that time.

    I don't know which pharmas they are in discussions with. But, they had a lot of meetings during the conference. One of which was important enough that Dr Alexander filled in as a presenter for Dr Jorgensen. Dr Jorgensen was in a meeting that must have been pretty important.

    And, look around and take note of all happening in the antibiotic space these days.

    Sounding like a shill or not, we are at a dip from the high that appears to be forming a bottom. Buying on dips is usually better than buying at the top. And, the fact remains, once a board is formed and the phase III results are in the price will be substantially higher.

    Thanks for reading my article and participating. ;)
    Jan 30, 2015. 05:52 PM | 3 Likes Like |Link to Comment
  • Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon [View article]
    dpudvay... first of all, there are three executives since Dr Alexander has been added as a COO: http://bit.ly/1vh6NZa

    And, yes, they realize they need to establish an independent board to uplist. They are working on that and the board will be announced at time of uplisting.

    I met Leo, Dr Menon, and Dr Alexander for the first time this month at the Biotech Showcase and stayed around for the q&a asking questions with a few other investors. And, this subject came up.

    Aspire was also at the Biotech Showcase and has told management they'd be happy to give more funds to the company. The existing arrangement has worked well for both sides. Aspire does sell some, but, only enough to avoid having to report their ownership position. When they do sell, it's done in such a way to avoid hurting the company since they are an investor too.

    Thankfully, the company has a 75mil shelf in case they need it. I’m expecting a partnership for Brilacidin development, but, don’t expect it until after the Brilacidin phase 3 trial has started. The shelf allows the company to give a large pharma a stake. The shares should be higher when this happens. Even without a partner, the shelf is good to have since it gives the company needed funds to proceed and puts them in a better bargaining position. Shares will move up in price with the added value as the trials progress.

    Management had quite a few meetings at the Biotech Showcase earlier this month. I had tried to get an early meeting to do an interview, but, they were just too busy with meetings scheduled ahead. I had to wait my turn with everyone else for the q&a after the presentation. As a matter of fact, I never met Dr Jorgenson due to his being tied up in meetings during and after the presentation. They must have been important for him to miss the presentation. Dr Alexander took his place.

    Plus, the company isn't paying for all of the trials. For example, the upcoming Kevetrin phase 1b/2 trial in combination with cytarabine at the University of Bologna is being funded by the University. Cellceutix only supplies the drug.

    The Fox work is being done with a grant.

    The upcoming Brilacidin phase 3 trial will be cost around 6mil, or 12 if the FDA requires two. This is one of the things that will come out of a meeting with the FDA over the coming months.
    Jan 30, 2015. 05:17 PM | 1 Like Like |Link to Comment
  • Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon [View article]
    tadoboy... the high was $2.47 in Dec 2012 and that was well before the acquisition of Brilacidin. $4.80 is almost a double from that point. The current high came with the announcement of the FDA granting the QIDP designation. Watch what happens when the Brilacidin phase 3 ABSSSI trial starts in a few months.

    There was only one clinical trial in Dec 2012. Keep your eye on this site and you'll understand why the share price is on an overall uptrend. http://1.usa.gov/1CCGluY

    With a partnership and uplisting many will lose the opportunity to get in at current prices. I expect a board to be announced simultaneously with the uplisting announcement.
    Jan 30, 2015. 05:05 PM | 2 Likes Like |Link to Comment
  • Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon [View article]
    Tom Andries... What's amazing to me is that other pharma's ignored the Polymedix assets sitting in bankruptcy court and that Leo and Dr Menon recognized the potential and grabbed it up!

    Getting Brilacidin into a phase 2b with a lower dose to eliminate the side effects and come out with such positive results this quickly is amazing. I don't get why people don't understand this accomplishment?!?

    I'm not a stats person, but, those that are into the stats have told me to expect a 98% probability of a positive Brilacidin phase 3 outcome on the ABSSSI trial. This is why I say Brilacidin has derisked the company.

    One of the other trials can fail and we still have a winner due to the current regulatory climate with antibiotics. ;) It will come to market faster, especially, with the FDA having given Brilacidin the QIDP designation.
    Jan 30, 2015. 01:09 PM | 5 Likes Like |Link to Comment
  • Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon [View article]
    retiredpharma... It's not a concern to me for a variety of reasons. First of all, the CEO's track record. He has run the company with a frugal hand. I’m expecting him to continue to do so.

    I met Leo, Dr Menon, and Dr Alexander for the first time this month at the Biotech Showcase and stayed around for the q&a asking questions with a few other investors. And, this subject came up.

    Aspire was also at the Biotech Showcase and has told management they'd be happy to give more funds to the company. The existing arrangement has worked well for both sides. Aspire does sell some, but, only enough to avoid having to report their ownership position. When they do sell, it's done in such a way to avoid hurting the company since they are an investor too.

    Thankfully, the company has a 75mil shelf in case they need it. I’m expecting a partnership for Brilacidin development, but, don’t expect it until after the Brilacidin phase 3 trial has started. The shelf allows the company to give a large pharma a stake. The shares should be higher when this happens. Even without a partner, the shelf is good to have since it gives the company needed funds to proceed and puts them in a better bargaining position. Shares will move up in price with the added value as the trials progress.

    Management had quite a few meetings at the Biotech Showcase earlier this month. I had tried to get an early meeting to do an interview, but, they were just too busy with meetings scheduled ahead. I had to wait my turn with everyone else for the q&a after the presentation. As a matter of fact, I never met Dr Jorgenson due to his being tied up in meetings during and after the presentation. They must have been important for him to miss the presentation. Dr Alexander took his place.

    Plus, the company isn't paying for all of the trials. For example, the upcoming Kevetrin phase 1b/2 trial in combination with cytarabine at the University of Bologna is being funded by the University. Cellceutix only supplies the drug.

    The Fox work is being done with a grant.

    The upcoming Brilacidin phase 3 trial will be cost around 6mil, or 12 if the FDA requires two. This is one of the things that will come out of a meeting with the FDA over the coming months.

    No time for a longer answer…have to run out the door… Odds are high that someone else will fill in the blanks while I’m gone. There are many CTIX shareholders that are willing to share information regularly.
    Jan 30, 2015. 11:17 AM | 8 Likes Like |Link to Comment
  • Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon [View article]
    dangerb407.... this article is in response to two hit pieces. I'm just filling in the blanks about a few positive things the authors forgot to mention.
    Jan 30, 2015. 11:07 AM | 3 Likes Like |Link to Comment
  • Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon [View article]
    90217... it's been removed. The system was picking up Cubist CBSTZ as a nanocap. They've removed the ticker and the editor's note.
    Jan 30, 2015. 10:45 AM | 2 Likes Like |Link to Comment
  • Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon [View article]
    mjl962.... Look at my prior CTIX articles. This one was a bit more aggressive in response to the two recent short pieces. It wasn't written to pump.

    What the stock does in the short term doesn't matter to me since I expect it to rise dramatically in the long run. $3 or $4 down here simply doesn't matter.

    And, yes, there is risk, but, Brilacidin has derisked it.
    Jan 29, 2015. 06:04 PM | 13 Likes Like |Link to Comment
  • Cellceutix: A December To Remember May Turn Into A 2015 To Forget For CTIX [View article]
    BuyersStrikeWP... most of the information regarding Dr Menon putting out false information is incorrect. I researched it a couple of years ago when this first surfaced. Apparently, the article in India that came out with some major falsehoods was pulled. And, then there was some confusion in the translations from English to Indian and back again to English in a publication that posted his credentials. Dr Mennon was at Dana Farber at the time ... Harvard. Then, to compound matters it was picked up in an online resume that nnvc produced when he was doing some work for them with his CRO KARD. That resume has since been pulled.

    In the meantime, the incorrect resume from that site has been copied around the net and gone viral. The correct resume is on the Cellceutix site. It's really a shame to see it printed again in Seeking Alpha. The article should be pulled.
    Jan 26, 2015. 09:09 AM | 1 Like Like |Link to Comment
  • Cellceutix: A December To Remember May Turn Into A 2015 To Forget For CTIX [View article]
    frrol... click on the link claiming to show that Dr Menon lied about his credentials. You'll find the section was quoted from an erroneous article without the author looking at the link. I've reported it to SA as a link that doesn't show what it's supposed to. Hopefully, the author or SA take it out.

    I checked into this when the first erroneous article came out and decided that the mistake on the other site wasn't Dr Menon's. And, it was not only corrected, it was taken out completely.

    Brilacidin having successfully, completed a phase IIb with one dose for one day vs daptomycin twice daily 7 days dosage is what most are looking at when they bid the price up. That and the QIDP designation. Brilacidin should have a phase III ABSSSI trial starting soon. Based on the data out thus far on the phase IIa and the phase IIb there is a 98% probability this phase III will be successful. That's still not a guarantee, but, I like the odds. Brilacidin has substantially derisked this investment.

    The science is what will make or break this company.

    Kevetrin phase I data slowly coming out is looking promising, but, it's too early to say how that story ends.

    Aspire was at the Biotech Showcase and is willing to give Cellceutix more capital if they should want it.

    There is a shelf in place to raise more funds if needed. Interestingly, Cellceutix isn't paying for all of the trials. For example, the upcoming Kevetrin trial at the University of Bologna will be covered by the University. Cellceutix only provides the Kevetrin.
    Jan 24, 2015. 12:17 PM | 5 Likes Like |Link to Comment
  • Cellceutix: A December To Remember May Turn Into A 2015 To Forget For CTIX [View article]
    Bleecker ... considering Dr Frei's position at Dana-Farber, they wouldn't be hosting the Kevetrin trial if that retracted Indian piece was true.
    ...
    You should also post the entire exchange with the CEO so reader's can see full context.
    ...
    Btw, the moment you published part of it you made it a public exchange.
    Jan 23, 2015. 05:10 PM | 8 Likes Like |Link to Comment
  • Tekmira/Oncore Merger Represents Substantial Upside [View article]
    Jester1711... Yes, you are correct...
    Jan 23, 2015. 10:50 AM | Likes Like |Link to Comment
  • Cellceutix: A December To Remember May Turn Into A 2015 To Forget For CTIX [View article]
    The article has some inaccuracies and twists a bit. I might respond to it fully, but, don't have time to do so now.

    The only thing I can see that is accurately presented in this article is the Cellceutix typo on one of their slides. The word assets is missing. If you look at the pr's you'll see they clearly reference to the PolyMedix acquisition as an asset purchase.

    http://bit.ly/1yS3eqm
    Jan 23, 2015. 10:47 AM | 18 Likes Like |Link to Comment
COMMENTS STATS
400 Comments
672 Likes